The GH–IGF-1 Axis: How Growth Hormone Drives IGF-1 Production

Research Disclaimer: All compounds referenced are sold exclusively for in-vitro and laboratory research use. Not approved for human therapeutic use. This content does not constitute medical advice.

The GH–IGF-1 axis is one of the most important hormonal systems in mammalian biology — it controls growth, body composition, and tissue homeostasis throughout life. Understanding how GH drives IGF-1 production, and how IGF-1 then mediates GH's effects at target tissues, is foundational for interpreting any GH research. This article covers the complete axis: from pituitary GH release through hepatic IGF-1 production to tissue-level signaling and feedback.

The Somatotropic Axis: Overview#

The somatotropic (GH–IGF-1) axis consists of:

1. Hypothalamus → releases GHRH (stimulates GH) and somatostatin (inhibits GH)
2. Anterior pituitary → somatotrophs secrete GH in response to GHRH
3. Liver → primary site of GH-stimulated IGF-1 production; also produces IGFBP-3 and ALS
4. Peripheral tissues → respond to circulating IGF-1 AND produce local IGF-1 in response to tissue-level GH signaling

Why GH needs IGF-1#

Early experiments showed that hypophysectomy (pituitary removal) stunts growth. Implanting GH-secreting tumor cells restores growth. The question was: does GH act directly on tissues, or through an intermediate?

The somatomedin hypothesis (Salmon and Daughaday, 1957) proposed that GH acts by stimulating liver production of a secondary mediator — which was later identified as IGF-1. The hypothesis proved largely correct: most of GH's growth-promoting and anabolic effects require hepatic IGF-1 production.

GH-Driven Hepatic IGF-1 Production#

The JAK2/STAT5 pathway in hepatocytes#

When GH binds GHR on hepatocytes:

1. GHR dimerization → JAK2 transphosphorylation and activation
2. JAK2 phosphorylates GHR intracellular tyrosines → creates docking sites for STAT5
3. JAK2 phosphorylates STAT5b (the dominant hepatic isoform)
4. Phospho-STAT5b dimerizes and translocates to the nucleus
5. Phospho-STAT5b binds GAS elements in the IGF-1 gene promoter → transcriptional activation
6. IGF-1 mRNA is produced, translated to IGF-1 precursor protein → processed and secreted

STAT5b (not STAT5a) is the dominant isoform for hepatic IGF-1 production:

• STAT5b knockout mice have drastically reduced IGF-1 (~30% of normal)
• STAT5b knockout is clinically relevant: rare human STAT5b loss-of-function mutations cause GH-insensitivity syndrome with normal GH but very low IGF-1

Magnitude of GH's effect on IGF-1#

A single GH pulse in healthy adults produces:

• Peak GH at ~15–30 minutes
• IGF-1 begins rising ~2 hours after the GH peak
• IGF-1 peaks 8–12 hours after the GH pulse
• The lag reflects time for hepatic transcription, translation, protein processing, and secretion

For sustained IGF-1 elevation, the GH pulsation frequency matters:

• More frequent, larger GH pulses → higher steady-state IGF-1
• Sparse or low-amplitude pulses (as in GH deficiency) → low IGF-1
• Continuous GH (non-pulsatile) → initially elevated IGF-1, but downregulation of GHR over time reduces sensitivity

IGF-1: Structure and the IGFBPs#

IGF-1 structure#

IGF-1 is a 70 amino acid peptide with:

• Four domains (A, B, C, D) — homologous to proinsulin
• Three disulfide bonds: stabilize the tertiary structure (required for IGF-1R binding)
• Molecular weight: 7,649 Da

The IGFBP system#

Free IGF-1 has a plasma half-life of only ~10 minutes. However, IGF-1 circulates bound to insulin-like growth factor binding proteins (IGFBPs 1–6):

The ternary complex (IGF-1 + IGFBP-3 + ALS) accounts for ~80% of circulating IGF-1 and has a plasma half-life of 12–15 hours — this complex is the "slow pool" of IGF-1 that maintains basal IGF-1 bioavailability between GH pulses.

GH drives not just IGF-1 but also IGFBP-3 and ALS production — so GH increases both the amount of IGF-1 and the carrier system that keeps it bioavailable.

What the IGFBPs do#

IGFBPs serve multiple functions:

1. Prolong IGF-1 half-life: the major carrier function
2. Transport IGF-1 to target tissues: the complex extravasates; proteases at target tissues release free IGF-1 locally
3. Inhibit IGF-1R binding (when IGF-1 is bound to IGFBP): the IGFBP-bound IGF-1 cannot bind IGF-1R — the IGFBPs act as a "reservoir" that protects against hypoglycemia from free IGF-1
4. Local bioavailability regulation: IGFBP proteases (e.g., pregnancy-associated plasma protein-A, PAPPA) cleave IGFBPs at tissue level → releases free IGF-1 locally → enhances local IGF-1R signaling at the tissue of interest

The IGFBP system is therefore not just a carrier mechanism — it is a tissue-specific IGF-1 delivery system regulated by local protease activity.

IGF-1 Receptor Signaling#

IGF-1R structure#

IGF-1R is a receptor tyrosine kinase (RTK):

• Heterotetrameric structure: (αβ)₂ — two extracellular α subunits + two transmembrane β subunits
• α subunits: ligand binding
• β subunits: intracellular tyrosine kinase domains
• Closely homologous to the insulin receptor (~50% sequence identity)

Key signaling pathways from IGF-1R#

PI3K/Akt/mTOR (primary anabolic/anti-apoptotic pathway):

• IGF-1R → IRS-1 phosphorylation → PI3K (p110/p85) recruitment and activation
• PI3K → PIP3 → PDK1 → Akt (S473 + T308 phosphorylation = full activation)
• Akt → mTORC1 (via TSC1/2 inhibition and RAPTOR phosphorylation)
• mTORC1 → S6K1 phosphorylation → ribosomal protein synthesis (muscle protein anabolism)
• mTORC1 → 4EBP1 phosphorylation → cap-dependent translation initiation
• Akt → FoxO1/3 phosphorylation → nuclear exclusion → suppresses atrogenes (MuRF-1, MAFbx) → inhibits protein catabolism

MAPK/ERK (proliferation/differentiation):

• IGF-1R → Shc/Grb2/SOS → Ras → RAF → MEK1/2 → ERK1/2
• ERK → cell proliferation, differentiation (satellite cells, fibroblasts)
• Less critical for acute muscle hypertrophy, more important for cell number increases

IRS-2 (alternative insulin receptor substrate):

• IRS-2 downstream of IGF-1R drives PI3K in some cell types; IRS-1 dominates in muscle

The mTORC1/S6K1/4EBP1 arm is the molecular switch for muscle protein synthesis — this is the mechanism by which elevated IGF-1 (from GH secretagogues or rhGH) drives hypertrophy.

GH vs. IGF-1 Direct Effects: A Critical Distinction#

Not every GH effect requires IGF-1. Published research using various experimental designs has identified which effects are GH-direct vs. IGF-1-mediated:

Evidence from dissociation experiments#

The clearest evidence for dissociating GH from IGF-1 effects comes from:

1. Liver-specific IGF-1 knockout (LID) mice: circulating IGF-1 reduced 75%, but postnatal growth is nearly normal → suggests GH-direct effects on growth plate compensate
2. IGF-1 infusion in GH-deficient hypophysectomized animals: IGF-1 alone restores many (but not all) GH-deficiency phenotypes
3. GH receptor antagonist (pegvisomant): blocks GH signaling → reduces IGF-1 dramatically → muscle atrophy + fat gain, confirming IGF-1's role in body composition

Negative Feedback: How the Axis Regulates Itself#

IGF-1 negative feedback#

Elevated IGF-1 provides negative feedback to the GH axis at multiple levels:

• Hypothalamus: IGF-1 stimulates somatostatin release → suppresses GH pulsation
• Hypothalamus: IGF-1 inhibits GHRH neurons → reduces GH stimulus
• Pituitary somatotrophs: IGF-1 directly inhibits GH gene transcription (via STAT5 feedback and direct IGF-1R signaling in somatotrophs)

GH negative feedback (short-loop)#

GH also provides short-loop feedback:

• GH → hypothalamus → increased somatostatin, decreased GHRH → GH pulse termination

Implications for GH secretagogue research#

These feedback loops mean that GH secretagogues (Ipamorelin + CJC-1295) face regulatory resistance as IGF-1 rises:

• Elevated IGF-1 from the secretagogue protocol → hypothalamic somatostatin → blunts subsequent GH pulses
• This is a natural regulatory ceiling — unlike rhGH (which bypasses the feedback loop), secretagogues operate within the body's GH-regulating system
• Result: GH secretagogue-induced IGF-1 elevation plateaus at a level below what rhGH can achieve at high doses, but also below the level that would cause significant GH-receptor downregulation

Measuring the Axis in Research#

Serum IGF-1 as the primary pharmacodynamic endpoint#

Because GH has a half-life of ~20 minutes, point-in-time GH measurements are variable and unreliable as chronic endpoint measurements. Serum IGF-1 (measured by ELISA or RIA) is preferred for chronic GH research protocols because:

• IGF-1 integrates GH exposure over hours
• IGF-1 is stable in serum and easy to measure
• IGF-1 correlates well with GH AUC in chronic studies

IGF-1/IGFBP-3 ratio#

IGFBP-3 (the major IGF-1 carrier) is also GH-driven. The IGF-1/IGFBP-3 molar ratio is used as an estimate of free IGF-1 bioavailability:

• If IGF-1 rises proportionally more than IGFBP-3, free IGF-1 bioavailability increases
• If IGFBP-3 rises proportionally more, more IGF-1 is bound and less is freely available to tissues

This distinction matters for interpreting body composition effects — it is the free IGF-1 that binds IGF-1R.

Key References#

1. Kopchick JJ, Andry JM. (2000). "Growth hormone (GH), GH receptor, and signal transduction." Molecular Genetics and Metabolism, 71(1-2):293–314.

2. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. (1995). "Molecular and cellular aspects of the insulin-like growth factor I receptor." Endocrine Reviews, 16(2):143–163.

3. Salmon WD Jr, Daughaday WH. (1957). "A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro." Journal of Laboratory and Clinical Medicine, 49(6):825–836.

4. Sims NA, Martin TJ. (2014). "Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit." BoneKEy Reports, 3:481.

5. Yakar S, et al. (2002). "Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity." Diabetes, 50(5):1110–1118.

Research Use Only: All compounds referenced are sold exclusively for in-vitro research and laboratory use. Not for human consumption. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Growth Hormone